Skip to main content
Literatur
1.
Zurück zum Zitat Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to Moderate Muscular Symptoms with High Dosage Statin Therapy in Hyperlipidemic Patients-the PRIMO Study. Cardiovasc Drugs Ther. 2005;19:402–14.CrossRef Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to Moderate Muscular Symptoms with High Dosage Statin Therapy in Hyperlipidemic Patients-the PRIMO Study. Cardiovasc Drugs Ther. 2005;19:402–14.CrossRef
2.
Zurück zum Zitat Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction (EPlerenone’s neuroHormonal Efficacy and SUrvival Study). Cardiovasc Drugs Ther. 2001;15:79–87. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction (EPlerenone’s neuroHormonal Efficacy and SUrvival Study). Cardiovasc Drugs Ther. 2001;15:79–87.
3.
Zurück zum Zitat Smith C, Davidson S, Lim S, Simpkin J, Hothersall J, Yellon D. Necrostatin: a Potentially Novel Cardioprotective Agent? Cardiovasc Drugs Ther. 2007;21:227–33.CrossRef Smith C, Davidson S, Lim S, Simpkin J, Hothersall J, Yellon D. Necrostatin: a Potentially Novel Cardioprotective Agent? Cardiovasc Drugs Ther. 2007;21:227–33.CrossRef
4.
Zurück zum Zitat Burke J, Dennis E. Phospholipase A2 Biochemistry. Cardiovasc Drugs Ther. 2009;23:49–59.CrossRef Burke J, Dennis E. Phospholipase A2 Biochemistry. Cardiovasc Drugs Ther. 2009;23:49–59.CrossRef
5.
Zurück zum Zitat Mitra S, Goyal T, Mehta J. Oxidized LDL, LOX-1 and Atherosclerosis. Cardiovasc Drugs Ther. 2011;25:419–29.CrossRef Mitra S, Goyal T, Mehta J. Oxidized LDL, LOX-1 and Atherosclerosis. Cardiovasc Drugs Ther. 2011;25:419–29.CrossRef
6.
Zurück zum Zitat Mehta J, Khaidakov M, Hermonat P, Mitra S, Wang X, Novelli G. LOX-1: a New Target for Therapy for Cardiovascular Diseases. Cardiovasc Drugs Ther. 2011;25:495–500.CrossRef Mehta J, Khaidakov M, Hermonat P, Mitra S, Wang X, Novelli G. LOX-1: a New Target for Therapy for Cardiovascular Diseases. Cardiovasc Drugs Ther. 2011;25:495–500.CrossRef
7.
Zurück zum Zitat Tarkin J, Kaski JC. Update on Pharmacological Agents for Management of Chronic Stable Angina : Introduction. Cardiovasc Drugs Ther. 2016;30:339–40.CrossRef Tarkin J, Kaski JC. Update on Pharmacological Agents for Management of Chronic Stable Angina : Introduction. Cardiovasc Drugs Ther. 2016;30:339–40.CrossRef
8.
Zurück zum Zitat Kitakaze M. How to Mediate Cardioprotection in Ischemic Hearts-Accumulated Evidence of Basic Research Should Translate to Clinical Medicine. Cardiovasc Drugs Ther. 2010;24:217–23.CrossRef Kitakaze M. How to Mediate Cardioprotection in Ischemic Hearts-Accumulated Evidence of Basic Research Should Translate to Clinical Medicine. Cardiovasc Drugs Ther. 2010;24:217–23.CrossRef
9.
Zurück zum Zitat Davidson SM. Editorial to: Building a Bridge to the Future of Cardiovascular Drugs and Therapy. Cardiovasc Drugs Ther. 2017;31:51–2.CrossRef Davidson SM. Editorial to: Building a Bridge to the Future of Cardiovascular Drugs and Therapy. Cardiovasc Drugs Ther. 2017;31:51–2.CrossRef
10.
Zurück zum Zitat Mehta JL. Women and Heart Disease; a Focus Issue. Cardiovasc Drugs Ther. 2015;29:317–8.CrossRef Mehta JL. Women and Heart Disease; a Focus Issue. Cardiovasc Drugs Ther. 2015;29:317–8.CrossRef
11.
Zurück zum Zitat Chen YE. Editorial: the Yin and Yang of Perivascular Adipose Tissue in Vascular Disease. Cardiovasc Drugs Ther. 2018;32:477–9.CrossRef Chen YE. Editorial: the Yin and Yang of Perivascular Adipose Tissue in Vascular Disease. Cardiovasc Drugs Ther. 2018;32:477–9.CrossRef
12.
Zurück zum Zitat Remme CA, Wilde A. Late Sodium Current Inhibition in Acquired and Inherited Ventricular (Dys)function and Arrhythmias. Cardiovasc Drugs Ther. 2013;27:91–103.CrossRef Remme CA, Wilde A. Late Sodium Current Inhibition in Acquired and Inherited Ventricular (Dys)function and Arrhythmias. Cardiovasc Drugs Ther. 2013;27:91–103.CrossRef
13.
Zurück zum Zitat Rosenson R, Koenig W. Special Issue on Biological Causality: When Experimental Models and Human Genetics Conflict. Mendelian Randomization Analysis for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. Cardiovasc Drugs Ther. 2016;30(1):65–74.CrossRef Rosenson R, Koenig W. Special Issue on Biological Causality: When Experimental Models and Human Genetics Conflict. Mendelian Randomization Analysis for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. Cardiovasc Drugs Ther. 2016;30(1):65–74.CrossRef
14.
Zurück zum Zitat Rosenson R. Special Section: Phospholipase, Inflammation and Cardiovascular Disease. Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2009;23:93–101.CrossRef Rosenson R. Special Section: Phospholipase, Inflammation and Cardiovascular Disease. Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2009;23:93–101.CrossRef
Metadaten
Titel
My Last Issue—a Farewell to Cardiovascular Drugs and Therapy
verfasst von
Willem J. Remme
Publikationsdatum
01.12.2019
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2019
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-019-06928-3

Weitere Artikel der Ausgabe 6/2019

Cardiovascular Drugs and Therapy 6/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.